Want to see HK:1110 full AI Analyst Report?
Top Page
Kingworld Medicines Group Ltd.
(1110)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$0.40
▼(-23.77% Downside)
Action:Reiterated
Date:07/15/26
The score is primarily held back by weakening financial performance (declining revenue and sharply lower profitability, alongside rising leverage and volatile free cash flow). Technical indicators are also soft with negative MACD and the price below longer-term moving averages. These negatives are partially offset by a strong dividend yield, though the P/E is not particularly cheap.
Positive Factors
Healthcare Distribution Platform
Serving pharmacies, hospitals, and other healthcare channels gives the company a defined position in essential healthcare distribution. This multi-channel model can support recurring product demand and broaden revenue access across professional and retail-facing customers over the next several quarters.
Negative Factors
Revenue Contraction
The shift from earlier growth to consecutive revenue declines signals weakening sales momentum in the company’s core distribution activities. Continued contraction would reduce operating leverage, limit purchasing scale, and make it harder to spread fixed costs across the existing healthcare product and channel base.
Read all positive and negative factors
Positive Factors
Negative Factors
Healthcare Distribution Platform
Serving pharmacies, hospitals, and other healthcare channels gives the company a defined position in essential healthcare distribution. This multi-channel model can support recurring product demand and broaden revenue access across professional and retail-facing customers over the next several quarters.
Read all positive factors
Kingworld Medicines Group Ltd. (1110) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$242.60M
Dividend Yield7.92%
Average Volume (3M)2.62M
Price to Earnings (P/E)18.1
Beta (1Y)0.36
Revenue Growth-13.82%
EPS Growth112.24%
CountryHK
Employees711
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.02
Shares Outstanding622,499,940
10 Day Avg. Volume3,994,000
30 Day Avg. Volume2,624,266
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)0.44
Price to Sales (P/S)0.30
P/FCF Ratio4.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kingworld Medicines Group Ltd. Business Overview & Revenue Model
Company Description
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and g...
How the Company Makes Money
Kingworld Medicines Group Ltd. primarily makes money by selling pharmaceutical and healthcare products through wholesale/distribution and related sales activities. Key revenue streams typically include: (1) distribution/wholesale revenue from purc...
Kingworld Medicines Group Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
58
Neutral
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 787.87M | 917.34M | 1.06B | 1.08B | 957.70M | 847.39M |
| Gross Profit | 240.04M | 247.91M | 270.45M | 280.67M | 277.63M | 263.60M |
| EBITDA | 75.09M | 72.03M | 100.46M | 125.48M | 118.07M | 116.00M |
| Net Income | 11.47M | 11.28M | 41.56M | 38.10M | 22.74M | 30.32M |
Balance Sheet | ||||||
| Total Assets | 1.30B | 1.44B | 1.42B | 1.34B | 1.26B | 1.21B |
| Cash, Cash Equivalents and Short-Term Investments | 188.35M | 274.70M | 249.60M | 194.03M | 256.17M | 198.41M |
| Total Debt | 438.04M | 434.05M | 402.44M | 354.43M | 290.68M | 238.96M |
| Total Liabilities | 648.92M | 753.86M | 710.04M | 638.30M | 569.15M | 493.19M |
| Stockholders Equity | 596.45M | 617.97M | 639.79M | 619.03M | 615.58M | 616.90M |
Cash Flow | ||||||
| Free Cash Flow | 49.03M | 54.92M | 94.73M | -63.25M | 93.64M | 22.88M |
| Operating Cash Flow | 78.67M | 84.56M | 135.82M | 42.28M | 186.55M | 81.20M |
| Investing Cash Flow | -12.59M | -20.11M | -27.64M | -120.63M | -84.05M | -50.84M |
| Financing Cash Flow | -28.62M | -30.82M | -47.61M | 4.37M | -51.31M | -87.20M |
Kingworld Medicines Group Ltd. Technical Analysis
Negative
0.53
Price Trends
0.43
Negative
0.43
Negative
0.47
Negative
Market Momentum
-0.01
Positive
40.53
Neutral
39.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1110, the sentiment is Negative. The current price of 0.53 is above the 20-day moving average (MA) of 0.43, above the 50-day MA of 0.43, and above the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.53 is Neutral, neither overbought nor oversold. The STOCH value of 39.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1110.
Kingworld Medicines Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$763.52M | 7.66 | 13.59% | 7.55% | 10.63% | 39.44% | |
54 Neutral | HK$211.70M | -0.19 | -154.56% | ― | -7.12% | -523.61% | |
52 Neutral | HK$242.60M | 18.07 | 1.89% | 7.92% | -13.82% | 112.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$221.45M | -6.02 | -8.05% | 2.26% | 12.89% | -2.56% | |
49 Neutral | HK$367.75M | 91.67 | 0.34% | 84.69% | -8.30% | -44.44% | |
43 Neutral | HK$139.08M | -4.57 | -21.66% | 0.48% | -6.71% | 43.14% |
* Healthcare Sector Average
HK:1110
Kingworld Medicines Group Ltd.
0.40
-0.14
-25.93%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.07
-0.04
-37.61%
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.06
-34.81%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.33
-0.05
-13.16%
HK:1498
PuraPharm Corp. Ltd.
0.26
-0.18
-40.91%
HK:0239
Pak Fah Yeow International Limited
2.45
0.14
5.97%
Kingworld Medicines Group Ltd. Corporate Events
Kingworld Medicines Narrows Shareholder Loss Despite Sharp Revenue Decline
Aug 27, 2026
Kingworld Medicines Group Ltd., a pharmaceutical and healthcare products distributor in mainland China with supplementary income from investment properties and equity interests, reported mixed interim results for the six months ended 30 June 2026....
Kingworld Medicines Schedules Board Meeting to Review Interim Results and Dividend
Aug 14, 2026
Kingworld Medicines Group Ltd. has announced that its board of directors will convene on 27 August 2026 in Hong Kong to review and approve the unaudited interim results for the six months ended 30 June 2026. The meeting will also consider the reco...
Kingworld Medicines Ends Proposed Acquisition, Seeks Refund of Deposit
Jun 15, 2026
Kingworld Medicines Group Ltd. has terminated a memorandum of understanding for a proposed acquisition of the entire issued share capital of a target company, exercising its contractual right to end the deal with immediate effect on June 15, 2026....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.